SiRNA for influenza therapy

Viruses

Volumn 2, Issue 7, 2010, Pages 1448-1457

  Barik, Sailen ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Antiviral; Influenza virus; RNA interference; Short interfering RNA

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE; POLYETHYLENEIMINE; SMALL INTERFERING RNA; ZANAMIVIR;

ASTHMA; BRONCHOSPASM; COUGHING; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG SPECIFICITY; FACE EDEMA; GERIATRIC PATIENT; HEADACHE; HUMAN; IMMUNOCOMPROMISED PATIENT; INFANCY; INFLUENZA; INFLUENZA VIRUS; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PARANASAL SINUS DISEASE; PREVALENCE; RESPIRATORY VIRUS; REVIEW; RNA INTERFERENCE; SORE THROAT; VIRUS MUTATION; VIRUS REPLICATION;

ORTHOMYXOVIRIDAE;

EID: 79952161658     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2071448     Document Type: Review

References (42)

1. Saladino, R.; Barontini, M.; Crucianelli, M.; Nencioni, L.; Sgarbanti, R.; Palamara, A.T. Current Advances in Anti-Influenza Therapy. Curr. Med. Chem. 2010, doi: 10.2174/ 092986710791299957.
2. Schmolke, M.; García-Sastre, A. Evasion of innate and adaptive immune responses by influenza A virus. Cell. Microbiol. 2010, doi: 10.1111/j.1462-5822.2010.01475.x.
3. Bouvier, N.M.; Palese, P. The biology of influenza viruses. Vaccine 2008, 26 (Suppl. 4), D49-53.
4. Tumpey, T.M.; Belser, J.A. Resurrected pandemic influenza viruses. Annu. Rev. Microbiol. 2009, 63, 79-98.
5. Bitko, V.; Musiyenko, A.; Barik S. Viral infection of the lungs through the eye. J. Virol. 2007, 81, 783-790.
6. Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391, 806-811.
7. Fire, A.Z. Gene silencing by double-stranded RNA. Cell Death Differ. 2007, 14, 1998-2012.
8. Elbashir, S.M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411, 494-498.
9. Bitko, V.; Barik, S. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol. 2001, 1, 34.
10. Ge, Q.; McManus, M.T.; Nguyen, T.; Shen, C.H.; Sharp, P.A.; Eisen, H.N.; Chen, J. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 2718-2723.
11. Barik, S. Control of nonsegmented negative-strand RNA virus replication by siRNA. Virus Res. 2004, 102, 27-35.
12. Ge, Q.; Filip, L.; Bai, A.; Nguyen, T.; Eisen, H.N.; Chen, J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 8676-8681.
13. Tompkins, S.M.; Lo, C.Y.; Tumpey, T.M.; Epstein, S.L. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 8682-8686.
14. Hirsch, A.J. The use of RNAi-based screens to identify host proteins involved in viral replication. Future Microbiol. 2010, 5, 303-311.
15. Yang, H.; Kim, S.K.; Kim, M.; Reche, P.A.; Morehead, T.J.; Damon, I.K.; Welsh, R.M.; Reinherz, E.L. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 2005, 115, 379-387.
16. Briz, V.; Poveda, E.; Soriano, V. HIV entry inhibitors: mechanisms of action and resistance pathways. J. Antimicrob. Chemother. 2006, 57, 619-627.
17. Hao, L.; Sakurai, A.; Watanabe, T.; Sorensen, E.; Nidom, C.A.; Newton, M.A.; Ahlquist, P.; Kawaoka, Y. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 2008, 454, 890-893.
18. König, R.; Stertz, S.; Zhou, Y.; Inoue, A.; Hoffmann, H.H.; Bhattacharyya, S.; Alamares, J.G.; Tscherne, D.M.; Ortigoza, M.B.; Liang, Y.; Gao, Q.; Andrews, S.E.; Bandyopadhyay, S.; De Jesus, P.; Tu, B.P.; Pache, L.; Shih, C.; Orth, A.; Bonamy, G.; Miraglia, L.; Ideker, T.; García-Sastre, A.; Young, J.A.; Palese, P.; Shaw, M.L.; Chanda, S.K. Human host factors required for influenza virus replication. Nature 2010, 463, 813-817.
19. Karlas, A.; Machuy, N.; Shin, Y.; Pleissner, K.P.; Artarini, A.; Heuer, D.; Becker, D.; Khalil, H.; Ogilvie, L.A.; Hess, S.; Mäurer, A.P.; Müller, E.; Wolff, T.; Rudel, T.; Meyer, T.F. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 2010, 463, 818-822.
20. Satterly, N.; Tsai, P.L.; van Deursen, J.; Nussenzveig, D.R.; Wang, Y.; Faria, P.A.; Levay, A.; Levy, D.E.; Fontoura, B.M. Influenza virus targets the mRNA export machinery and the nuclear pore complex. Proc. Natl Acad. Sci. U.S.A. 2007, 104, 1853-1858.
21. Elton, D.; Simpson-Holley, M.; Archer, K.; Medcalf, L.; Hallam, R.; McCauley, J.; Digard, P. Interaction of the influenza virus nucleoprotein with the cellular CRM1-mediated nuclear export pathway. J. Virol. 2001, 75, 408-419.
22. Harborth, J.; Elbashir, S.M.; Bechert, K.; Tuschl, T.; Weber, K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J. Cell. Sci. 2001, 114 (Pt 24), 4557-4565.
23. Aszódi, A.; Pfeifer, A.; Ahmad, M.; Glauner, M.; Zhou, X.H.; Ny, L.; Andersson, K.E.; Kehrel, B.; Offermanns, S.; Fässler, R. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J. 1999, 18, 37-48.
24. Hoffman, L.M.; Nix, D.A.; Benson, B.; Boot-Hanford, R.; Gustafsson, E.; Jamora, C.; Menzies, A.S.; Goh, K.L.; Jensen, C.C.; Gertler, F.B.; Fuchs, E.; Fassler, R.; Beckerle, M.C. Targeted disruption of the murine zyxin gene. Mol. Cell. Biol. 2003, 23, 70-79.
25. Musiyenko, A.; Bitko, V.; Barik, S. RNAi-dependent and -independent antiviral phenotypes of chromosomally integrated shRNA clones: role of VASP in respiratory syncytial virus growth. J. Mol. Med. 2007, 85, 745-752.
26. Harpen, M.; Barik, T.; Musiyenko, A.; Barik, S. Mutational analysis reveals a noncontractile but interactive role of actin and profilin in viral RNA-dependent RNA synthesis. J. Virol. 2009, 83, 10869-10876.
27. Bitko, V.; Oldenburg, A.; Garmon, N.E.; Barik, S. Profilin is required for viral morphogenesis, syncytium formation, and cell-specific stress fiber induction by respiratory syncytial virus. BMC Microbiol. 2003, 3, 9.
28. Burke, E.; Mahoney, N.M.; Almo, S.C.; Barik, S. Profilin is required for optimal actin-dependent transcription of respiratory syncytial virus genome RNA. J. Virol. 2000, 74, 669-675.
29. Seth, S.; Templin, M.V.; Severson, G.; Baturevych, O. A potential therapeutic for pandemic influenza using RNA interference. Methods Mol. Biol. 2010, 623, 397-422.
30. Ge, Q.; Eisen, H.N.; Chen, J. Use of siRNAs to prevent and treat influenza virus infection. Virus Res. 2004, 102, 37-42.
31. Bitko, V.; Musiyenko, A.; Shulyayeva, O.; Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 2005, 11, 50-55.
32. Barik, S. Treating respiratory viral diseases with chemically modified, second generation intranasal siRNAs. Methods Mol. Biol. 2009, 487, 331-341.
33. Hornung, V.; Guenthner-Biller, M.; Bourquin, C.; Ablasser, A.; Schlee, M.; Uematsu, S.; Noronha, A.; Manoharan, M.; Akira, S.; de Fougerolles, A.; Endres, S.; Hartmann, G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 2005, 11, 263-270.
34. Judge, A.D.; Sood, V.; Shaw, J.R.; Fang, D.; McClintock, K.; MacLachlan, I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 2005, 23, 457-462.
35. Robbins, M.; Judge, A.; MacLachlan, I. siRNA and innate immunity. Oligonucleotides 2009, 19, 89-102.
36. Judge, A.; MacLachlan, I. Overcoming the innate immune response to small interfering RNA. Hum. Gene Ther. 2008, 19, 111-124.
37. Li, B.J.; Tang, Q.; Cheng, D.; Qin, C.; Xie, F.Y.; Wei, Q.; Xu, J.; Liu, Y.; Zheng, B.J.; Woodle, M.C.; Zhong, N.; Lu, P.Y. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med. 2005, 11, 944-951.
38. Gaglione, M.; Messere, A. Recent progress in chemically modified siRNAs. Mini Rev. Med. Chem. 2010, 10, 578-595.
39. Semple, S.C.; Akinc, A.; Chen, J.; Sandhu, A.P.; Mui, B.L.; Cho, C.K.; Sah, D.W.; Stebbing, D.; Crosley, E.J.; Yaworski, E.; et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 2010, 28, 172-176.
40. Davis, M.E.; Zuckerman, J.E.; Choi, C.H.; Seligson, D.; Tolcher, A.; Alabi, C.A.; Yen, Y.; Heidel, J.D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464, 1067-1070.
41. Gantier, M.P.; Tong, S.; Behlke, M.A.; Irving, A.T.; Lappas, M.; Nilsson, U.W.; Latz, E.; McMillan, N.A., Williams, B.R. Rational design of immunostimulatory siRNAs. Mol. Ther. 2010, 18, 785-795.
42. Gu, W.; Cochrane, M.; Leggatt, G.R.; Payne, E.; Choyce, A.; Zhou, F.; Tindle, R.; McMillan, N.A. Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 8314-8319.